Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 87.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2014 · 2.3K citations · Full text

Medicine, Nephrology, Oncology +14

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel, Andrés Cervantes, Ian Chau et al. · Annals of Oncology · 2018 · 1.1K citations · Full text

Medicine, Oncology, Surgery +14

Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data

Nicholas Latimer · Medical Decision Making · 2013 · 535 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17